- Global Pharma News & Resources

Portal Hypertension Management Market to reach US$ 4.97 billion by 2033, Endoscopic Procedures to rise at a 7% CAGR: FMI Study

The global portal hypertension management market is expected to be valued at US$ 3.05 billion in 2023, and will likely exhibit a compound annual growth rate (CAGR) of 5% from 2023 to 2033, concludes a recently published report by Future Market Insights. The generic pharmaceutical segment currently leads the market, with the scope of diagnosis including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs. This also indicates excellent potential for medicinal study and development.

One of the most frequent causes of portal hypertension is cirrhosis. Cirrhosis is a liver illness that occurs when scar tissue displaces healthy liver cells. As a consequence, the number of individuals suffering from this disease is expected to drive market expansion. Cirrhosis is more prevalent in males than in females, based on the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, the aged citizenry is anticipated to contribute to market expansion.

Get Latest Sample Copy@

High cost technological innovations in the health care system and ramping up prevalence and frequency of beta-blocker consumption, North America has the highest market portion. Due to its expanding elderly population and greater diagnosis percentage, Asia-Pacific has the second-largest market revenue. As a result of perpetual increases in the incidence and occurrence of rare diseases, as well as the enhancement inpatient population, North America is forecast to account for the majority of the market in the following decade

The expansion of the Liver Transplantation segment can be linked to the global rise in demand for transplantable organs. As reported by the U.S. Department of Health and Human Services, there were roughly 122,913 diagnoses in the United States ready for organ transplants in 2019. As a result, developed transplantation items for the intervention of organ damage are in high demand. As a result, the market for the Liver Transplantation segment is growing.

Ask An Analyst @

Key Takeaways from the Market Study

  • From 2018 to 2022, sales witnessed major growth, registering a CAGR of 3%
  • The global portal hypertension management market is predicted to garner a market value of US$ 97 Billion.
  • Portal hypertension management market in North America is expected to grow at a CAGR of 4%
  • Endoscopic therapy to be most preferred, expected to grow at a CAGR of 7%.
  • The Asia Pacific market is expected to account for 40% of the market share.

The therapies under advancement are focused on novel approaches to treating/improving disease signs. Companies involved are working on developing Portal Hypertension therapies. The launch of new treatments will have a significant impact on the portal hypertension management market.says FMI’s analyst.

Competitive Landscape

Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some recent developments by manufacturers are below

  • In August 2022, ONO received approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective 1 blocker.
  • In March 2021, Gilead Sciences announced that it would expand its collaboration with Novo Nordisk and gain knowledge of the prospects for composite strategies in helping patients with cirrhosis caused by NASH, contributing to the portal hypertension management market.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global portal hypertension management market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.

To understand opportunities in the portal hypertension management market, the market is segmented on the basis of treatment (liver transplantation, endoscopic therapy, shunting procedures, and drug class), and end users (hospitals, specialty clinics, and others) across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Request Discount@

Key Segments Profiled in the Portal Hypertension Management Industry Survey

By Treatment:

  • Liver Transplantation
  • Endoscopic Therapy
    • Banding
    • Balloon Tamponade
  • Shunting Procedures
    • Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
    • Surgical Shun
  • Drug Class
    • Octapeptides
    • Cofactors
    • PDE5 Inhibitor
    • Beta Blockers

By End Users:

  • Hospitals
  • Specialty Clinic
  • Others

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Editor Details

Last Updated: 08-Feb-2023